Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2008

01-06-2008 | Melanomas

Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy

Authors: F. J. Collinson, MBChB, T. K. Lam, MBBS, W. M. J. Bruijn, MD, PhD, J. H. W. de Wilt, MD, PhD, M. Lamont, MBBS, J. F. Thompson, MBBS, MD, R. F. Kefford, MBBS, PhD

Published in: Annals of Surgical Oncology | Issue 6/2008

Login to get access

Abstract

Background

Human melanoma cells express high-affinity glucocorticoid receptors, and adrenalectomy has been shown to have antimelanoma effects in animal models. Long-term regression of distant metastatic melanoma was observed in one patient after bilateral adrenalectomy, prompting a review of adrenalectomy for melanoma metastases performed at this center.

Methods

A retrospective study in which all patients treated at the Sydney Melanoma Unit and recorded as having adrenal gland metastases between January 1987 and January 2004 were identified and their survival analyzed.

Results

One hundred eighty-six patients with adrenal gland metastases were identified. Adrenalectomy was performed in 23 patients; the other 163 patients were treated nonsurgically. The adrenal glands were the sole site of disease in five patients. All symptomatic patients were free of pain after recovery from the surgical procedure. Thirteen patients were rendered clinically and radiologically disease-free by their surgery. There was no postoperative mortality within 30 days. Median overall survival after adrenalectomy was 16 months (2-year survival, 39%), compared with 5 months for patients with documented adrenal metastases treated nonsurgically (P < .00001). In one patient, nonresected visceral metastases elsewhere regressed completely after bilateral adrenalectomy; he remained well and free of disease 80 months after adrenalectomy. Regression of distant visceral metasatatic disease also occurred in a second patient after unilateral adrenalectomy.

Conclusions

Adrenalectomy for melanoma metastatic to the adrenal gland provides good palliation of symptoms and is associated with prolonged survival in a selected cohort of patients. We report for the first time sustained complete regression of distant metastatic melanoma after bilateral adrenalectomy, suggesting a possible role for adrenal hormones in modifying melanoma progression in certain patients.
Literature
1.
Branum GD, Epstein RE, Leight GS, et al. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 1991;109:127–31.PubMed
2.
Kefford RF. (2003) Management of the patient with advanced melanoma. In: Thompson JF, Morton DL, Kroon BBR (eds). Textbook of Melanoma. London: Martin Dunitz. pp 535–46
3.
Dao AH, Page DL, Reynolds VH, et al. Primary malignant melanoma of the adrenal gland. A report of two cases and review of the literature. Am Surg 1990;56:199–203.PubMed
4.
Das Gupta T, Brasfield R. Metastatic melanoma. A clinicopathological study. Cancer 1964;17:1323–39.CrossRef
5.
Akslen LA, Heuch I, Hartveit F. Metastatic patterns in autopsy cases of cutaneous melanoma. Invasion Metastasis 1988;8:193–204.PubMed
6.
Meyers ML, Balch CM. Diagnosis and treatment of metastatic melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S-J, (eds). Cutaneous Melanoma. St Louis: Quality Medical Publishing, 2003:325–72
7.
Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135:807–10.PubMedCrossRef
8.
Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–48.PubMed
9.
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–34.PubMed
10.
Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997;79:2345–53.PubMedCrossRef
11.
Wood TF, DiFronzo LA, Rose DM, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001;8:658–62.PubMedCrossRef
12.
Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687–701.PubMed
13.
Eigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748–59.PubMedCrossRef
14.
Lotze MT, Dallal RM, Kirkwood JM, et al. (2001) Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, Vol 2. Philadelphia: Lippincott, Williams & Wilkins. pp 2012–69
15.
Coit DG. Role of surgery for metastatic malignant melanoma: a review. Semin Surg Oncol 1993;9:239–45.PubMed
16.
Morton DL, Mozillo N, Thompson JF, et al. An international, randomized phase III trial of bacillus Calmette-Guérin (BCG) plus allogenic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007;25:8508.
17.
Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg 1991;162:428–31.PubMedCrossRef
18.
Gutman H, Hess KR, Kokotsakis JA, et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 2001;25:750–8.PubMedCrossRef
19.
Lejeune FJ, Lienard D, Sales F, et al. Surgical management of distant melanoma metastases. Semin Surg Oncol 1992;8:381–91.PubMedCrossRef
20.
Ollila DW, Essner R, Wanek LA, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg 1996;131:975–9, 979–80.PubMed
21.
22.
Heniford BT, Arca MJ, Walsh RM, et al. Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 1999;16:293–306.PubMedCrossRef
23.
Lo CY, van Heerden JA, Soreide JA, et al. Adrenalectomy for metastatic disease to the adrenal glands. Br J Surg 1996;83:528–31.PubMedCrossRef
24.
Haigh PI, Essner R, Wardlaw JC, et al. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol 1999;6:633–9.PubMedCrossRef
25.
Meyer T, Goehl J, Hohenberger W. Long-term survival after extended surgical resection of melanoma metastasis and immunotherapy. Eur J Surg Oncol 1999;25:105–6.PubMed
26.
Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–81.CrossRef
27.
Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181–90.PubMedCrossRef
28.
Sarela AI, Murphy I, Coit DG, et al. Metastasis to the adrenal gland: the emerging role of laparoscopic surgery. Ann Surg Oncol 2003;10:1191–6.PubMedCrossRef
29.
Crowley NJ, Seigler HF. Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 1992;127:1303–8.PubMed
30.
Yarnold JR, Cochrane JP. Malignant melanoma: significance of disease-free interval. Br J Radiol 1980;53:1068–70.PubMed
31.
MacGillivray DC, Shichman SJ, Ferrer FA, et al. A comparison of open vs laparoscopic adrenalectomy. Surg Endosc 1996;10:987–90.PubMedCrossRef
32.
MacGillivray DC, Whalen GF, Malchoff CD, et al. Laparoscopic resection of large adrenal tumors. Ann Surg Oncol 2002;9:480–5.PubMedCrossRef
33.
Prinz RA. A comparison of laparoscopic and open adrenalectomies. Arch Surg 1995;130:489–92.PubMed
34.
Castillo OA, Vitagliano G, Kerkebe M, et al. Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology 2007;69:637–41.PubMedCrossRef
35.
Kim SH, Brennan MF, Russo P, et al. The role of surgery in the treatment of clinically isolated adrenal metastasis. Cancer 1998;82:389–94.PubMedCrossRef
36.
Paul CA, Virgo KS, Wade TP, et al. Adrenalectomy for isolated adrenal metastases from non-adrenal cancer. Int J Oncol 2000;17:181–7.PubMed
37.
Wells SA, Merke DP, Cutler GB Jr, et al. Therapeutic controversy: the role of laparoscopic surgery in adrenal disease. J Clin Endocrinol Metab 1998;83:3041–9.PubMedCrossRef
38.
Hawkins EF, Horn D, Markland FS Jr. Receptor for glucocorticoids in RPMI 3460 melanoma cells. Cancer Res 1980;40:2174–8.PubMed
39.
Bhakoo HS, Milholland RJ, Lopez R, et al. High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst 1981;66:21–5.PubMed
40.
Adachi K, Kondo S, Hu F. Suppression of growth of mouse melanoma by cortisone. Nature 1968;220:1132–3.PubMedCrossRef
41.
Bhakoo HS, Paolini NS, Milholland RJ, et al. Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. Cancer Res 1981;41:1695–701.PubMed
42.
DiSorbo DM, McNulty B, Nathanson L. In vitro growth inhibition of human malignant melanoma cells by glucocorticoids. Cancer Res 1983;43:2664–7.PubMed
43.
Horn D, Buzard RL. Growth inhibition by glucocorticoids in RPMI 3460 melanoma cells. Cancer Res 1981;41:3155–60.PubMed
44.
Markland FS Jr, Horn D. Steroid hormone receptor studies in melanoma model systems. J Supramol Struct 1980;13:35–46.PubMedCrossRef
45.
Stanberry LR, Lindsey WF, Beattie CW. Effect of adrenal manipulation on glucocorticoid receptors in MM1 hamster melanoma. Cancer Res 1982;42:2242–6.PubMed
46.
Nathanson L. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 1976;44:67–76.PubMed
47.
O’Connell ME, Powell BW, O’Connell JM, et al. Spontaneous regression of multiple bone metastases in malignant melanoma. Br J Radiol 1989;62:1095–100.PubMedCrossRef
48.
Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol 1994;5:249–51.PubMed
Metadata
Title
Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy
Authors
F. J. Collinson, MBChB
T. K. Lam, MBBS
W. M. J. Bruijn, MD, PhD
J. H. W. de Wilt, MD, PhD
M. Lamont, MBBS
J. F. Thompson, MBBS, MD
R. F. Kefford, MBBS, PhD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9836-y

Other articles of this Issue 6/2008

Annals of Surgical Oncology 6/2008 Go to the issue

Melanomas

Criteria in Sentinel Lymph Nodes of Melanoma Patients that Predict Involvement of Nonsentinel Lymph Nodes

Multimedia Article

Laparoscopic Pelvic Autonomic Nerve-Preserving Surgery for Sigmoid Colon Cancer

Melanomas

Author Reply: Sentinel Lymph Node Biopsy in Cutaneous Melanoma

Bone and Soft Tissue Sarcomas

Knowledge Helps, but Alone It Is Not Enough

Gastrointestinal Oncology

Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation

Bone and Soft Tissue Sarcomas

Raloxifene Can Reduce Giant Cell Tumor Recurrence: A New Adjuvant Therapy